Cough Suppressive Therapy in Patients With Chronic Cough

Cough Suppressive Therapy in Chronic Cough: Randomized Controlled Trial

In this randomized, placebo-controlled, interventional study on chronic cough a non-pharmacological cough suppressive therapy is the intervention to be studied, with a control group receiving treatment consisting of general healthy lifestyle advice. The following data will be collected before, after and up to six months after treatment: Standardized questionnaires for diagnosis of background factors, Leicester Cough Questionnaire (LCQ), Work Ability Index (WAI), and cough frequency as well as lung function and biomarkers.

The primary treatment effect measurement will be changes in chronic cough-related quality of life, measured by the Leicester Cough Questionnaire (LCQ).

Study Overview

• Status: Recruiting
• Conditions: Chronic Cough
• Intervention / Treatment: Behavioral: Cough suppressive therapy; Behavioral: General healthy lifestyle instructions

Detailed Description

The study will be carried out in collaboration between respiratory physicians, clinical physiologists, physiotherapists, speech- and language therapists and gastroenterologists.

The primary hypothesis of the planned study is:

The cough suppressive therapy improves chronic cough-related quality of life and work ability, and is sustained over six months after treatment.

The secondary hypotheses of the planned study are:

Treatment of chronic cough by the cough suppressive therapy can reduce cough frequency (measured by an automated cough detector), airway inflammation and airway resistance.

Baseline differences in clinical findings, biomarkers and physiologic measurements predict different treatment effects.

The following data will be collected before and after treatment:

• Standardized questionnaires for diagnosis of background factors and cough duration, LCQ, WAI, questions on sick leave days, voice disturbance questionnaire.
• Physiological measurements: Spirometry with reversibility test, impulse oscillometry before and after provocation with hypertonic saline inhalation. 24 hours cough frequency analysis, voice analysis.
• Biomarkers: Fractional exhaled nitric oxide (FeNO), blood-eosinophils and eosinophil cationic protein in serum, proteomics in particles in exhaled air (PExA)

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Principal investigator, Phd; Phone Number: +46186110000; Email: lungforskning@akademiska.se

Study Locations

• Sweden
  • Uppsala, Sweden, 75185
    • Recruiting
    • Uppsala Academical Hopsital
    • Contact: Össur Emilsson, Phd; Email: ossur.emilsson@akademiska.se
    • Contact: Henrik Johansson, Phd; Email: henrik.johansson@akademiska.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Chronic cough (duration >2 months) without a structural lung disease and a normal chest X-ray, which have failed pharmacological treatment.
• Being able to understand the swedish language.

Exclusion Criteria:

• Pulmonary abnormalities on a chest X-ray, structural lung disease, or chronic obstructive pulmonary disease (COPD) of spirometry stage Global Initiative for Obstructive Lung Disease (GOLD) 2 or higher.
• Smoking under the last three months.
• Ongoing or recent treatment with angiotensin-converting enzyme (ACE) inhibitor
• Active aspiration, vocal cord nodules or upper respiratory tract infection in the previous 4 weeks.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cough suppressive therapy; The cough suppressive therapy consists of four one-to-one treatment sessions, 45 minutes per session, over a 2 months period. The sessions include patient education about chronic cough; negative effects of repeated cough as well as patient education of voluntary control of cough; identification of cough triggers and learning cough suppression techniques, and psychoeducational counselling including patient self-motivation, repetition of aims and techniques, behavior modification regarding over-awareness of the need to cough. The sessions will be conducted by a specially trained physiotherapist or speech and language therapist. All components of the cough suppressive therapy will be delivered to each participant but the focus and emphasis on individual techniques will be individually tailored for each participant, determined by the physio- or speech and language therapist together with the participant.	Behavioral: Cough suppressive therapy; The cough suppressive therapy based on the treatment regime "Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136).
Active Comparator: Healthy lifestyle instructions; The Healthy lifestyle instructions consists of four one-to-one treatment sessions, 30 minutes per session, over a 2 months period. The sessions will be conducted by a specially trained physiotherapist or speech and language therapist. The sessions include patient education and motivational conversation about healthy eating habits, physical activity, stress and relaxation.	Behavioral: General healthy lifestyle instructions; The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Leicester Cough Questionnaire (LCQ)	Leicester Cough Questionnaire (LCQ) is an English-born self-reporting quality of life measure of chronic cough,	Change from baseline LCQ at one week and 6 months after completed intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in The Work Ability Index (WAI)	WAI is a questionnaire, which serves to conduct a self-assessment. The focus is on the employees and their work ability assessed by themselves	Change from baseline WAI at one week and 6 months after completed intervention
Change in Cough frequency	24 hour consecutive recording of cough frequency in home environment	Change from baseline cough frequency at one week and 6 months after completed intervention
Change in the hypersensitivity of the cough reflex	Standardised provocation test with inhaled hypertonic saline	Change from baseline hypersensitivity of the cough reflex at one week after completed intervention
Change in inflammation biomarkers in blood; eosinophil count	Blood samples for eosinophil count, (cells/l)	Change from baseline inflammation biomarkers (eosinophil count) in blood at one week after completed intervention
Change in inflammation biomarker fractional exhaled nitric oxide (FeNO)	Measured exhaled nitric oxide (NO) at 50 mL/s using a chemiluminescence NO analyzer.	Change from baseline FeNo at one week after completed intervention
Change in inflammation biomarkers in blood; level of eosinophil cationic protein (ECP)	Blood samples for ECP (mcg/l)	Change from baseline inflammation biomarkers in blood (ECP) at one week after completed intervention

Collaborators and Investigators

• Sponsor: Uppsala University
• Investigators: Study Director: Helen Wallstedt, Uppsala Academical Hospital, Uppsala, Sweden

Study record dates

Study Major Dates

• Study Start (Anticipated): November 3, 2022
• Primary Completion (Anticipated): August 31, 2024
• Study Completion (Anticipated): December 31, 2024

Study Registration Dates

• First Submitted: August 22, 2022
• First Submitted That Met QC Criteria: August 30, 2022
• First Posted (Actual): August 31, 2022

Study Record Updates

• Last Update Posted (Actual): November 8, 2022
• Last Update Submitted That Met QC Criteria: November 2, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Cough
• Other Study ID Numbers: 974599

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No